Exscientia business update for second quarter and first half 2024

Oxford, u.k.--(business wire)--exscientia plc (nasdaq: exai): recent advancements in the company's pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2024, are summarised below. “last week, we announced that exscientia entered into a definitive agreement to combine with recursion pharmaceuticals,” said david hallett, ph.d., interim chief executive officer and chief scientific officer of exscientia. “when we bring together our platforms at.
EXAI Ratings Summary
EXAI Quant Ranking